Ahmar U. Zaidi/LinkedIn
Jun 14, 2026, 18:01
Ahmar U. Zaidi: The First Pivotal Study of a New Mechanism in Sickle Cell Disease
Ahmar U. Zaidi, Senior Medical Director of Clinical Development at Agios Pharmaceuticals, shared a post on LinkedIn:
“EHA plenary for the RISE UP study!
An incredible moment.
Not because the RISE UP study was on one of the biggest stages in hematology, but because of what it represented.
The first pivotal study of a new mechanism in Sickle Cell disease. The chance to help tell the story of a potential new treatment paradigm in sickle cell disease: PK activation.
There is immense gratitude for the patients, families, investigators, advocates, and colleagues who made this moment possible.
Progress in sickle cell disease belongs to all of them.
I am simply fortunate to be here while their story is told.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?